Angelman Syndrome
New Angelman syndrome research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), real-world studies described subtype-linked seizure burden and reported experiences with common antiseizure medicines, while preclinical UBE3A-restoration approaches expanded without patient results. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Seizure medicines in practice. Clinic data added detail on seizure burden and reported medication experiences.
- CBD for seizures. CBD updates came from separate clinical observations and mouse-model experiments.
- Sleep and caregiver support. Sleep burden was described in detail; caregiver support showed early feasibility.
- Tracking change measures. Outcome tools improved reliability and helped interpret small shifts.
- Disease-targeted research. More UBE3A-raising strategies were shown in lab and animals.
New
September 2026
- Seizure frequency. Clinic records found seizures were common and sometimes hard to control.
- Seizure medication effects. Several common seizure medicines were linked with fewer seizures in practice.
- Caregiver coping support. A small telehealth coping course was linked with better caregiver well-being.
- UBE3A gene activity. An antisense genetic medicine increased UBE3A activity in lab models.
August 2026
- Night sleep problems. Caregivers reported more night waking and snoring.
- Sleep questionnaires. Breathing questionnaires matched better than daytime sleepiness tools.
- EEG delta activity. A pig model showed higher delta brain waves, early evidence.
- Rare inheritance route. One family report described paternal transmission via mosaic chromosome changes.
July 2026
- Seizures by subtype. Deletion subtype was linked to more seizures or earlier epilepsy recognition.
- Rescue medicine use. Some caregivers reported no fast-acting seizure rescue medicine option.
- Delayed diagnosis. Limited genetic testing was linked to later Angelman syndrome diagnosis.
- Speech tracking tools. Two automated speech tools missed different kinds of speech.
June 2026
- Delta EEG subtypes. Two delta EEG signals linked to different abilities.
- CBD mouse findings. In mice, CBD changed sleep and lowered later seizure risk.
- Mixed drug effects. In a model, two related drugs had opposite seizure effects.
May 2026
- Tracking early communication. A caregiver-reported tool was scored in a way that better captured very early, low-level communication changes.
- Speech therapy access and coordination. Families described day-to-day benefits from therapy, but also reported ongoing gaps in access and coordination across providers.
- Raising UBE3A in neurons. Early lab studies increased UBE3A in neurons by targeting the Ube3a-ATS transcript that keeps the paternal copy of the gene silent.
- Signaling and metabolism changes. Exploratory studies linked UBE3A loss to specific shifts in cell signaling and metabolism in models of Angelman syndrome.
April 2026
- CBD and seizure frequency. In a real‑world report that included a 15q group with Angelman syndrome, highly purified cannabidiol (CBD) use was linked with fewer seizures.
- Reported changes beyond seizures. In the same report, some families also noted changes such as sleep, behavior, or attention, but these were not reported for everyone.
- HERC2 and protein recycling. A laboratory study linked the gene HERC2 to how cells tag and assemble the proteasome, a system that breaks down and recycles proteins.
March 2026
- Eye differences by subtype. In this report, the deletion subtype was linked with more astigmatism and lighter-colored irises.
- Strabismus surgery outcomes. After strabismus surgery, eye alignment at 1 year was reported as similar across genetic subtypes.
- More accurate pig genome region. Researchers rebuilt an Angelman-related region in the pig genome to make that reference sequence more accurate for research use.
- Mouse learning test reliability. In a mouse model, operant learning testing measured learning changes more consistently than some other behavior measures.
February 2026
- Add-on cannabidiol use. In a hard-to-treat pediatric epilepsy clinic group, add-on cannabidiol was often continued for 12–24 months, with seizure reduction commonly reported but not reported specifically for Angelman syndrome.
- Meaningful communication change. Early cutoffs were proposed for what counts as a meaningful change on a caregiver communication questionnaire, to help judge whether a score shift likely reflects a real-life change.
- At-home video skill tracking. At-home video methods were described to assess functional skills remotely, but the available summary did not report results on how well the approach worked.
- UBE3A measurement tools. Mouse and neuron-model studies suggested UBE3A changes may affect behavior and seizure biology differently, and new tools were developed to measure UBE3A changes more directly in early testing.
January 2026
- Repeatable communication scores. Caregiver-reported communication scores were similar when the same questionnaire was repeated about two weeks apart, supporting their use for tracking change over time.
- What counts as a real change. Caregivers did not view one fixed score change as meaningful for everyone, and expectations depended on a person’s starting abilities.
- Genetic subtype differences. Deletion versus non-deletion subtypes were linked to group differences in communication scores and in how often epilepsy was reported.
- Sleep and feeding in lab models. Animal and lab studies connected UBE3A-related biology to lower melatonin production and to feeding changes, but these findings are research tools rather than clinical results.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Angelman syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).